JP3209427B2 - 創傷または痔疾治療剤 - Google Patents

創傷または痔疾治療剤

Info

Publication number
JP3209427B2
JP3209427B2 JP51394793A JP51394793A JP3209427B2 JP 3209427 B2 JP3209427 B2 JP 3209427B2 JP 51394793 A JP51394793 A JP 51394793A JP 51394793 A JP51394793 A JP 51394793A JP 3209427 B2 JP3209427 B2 JP 3209427B2
Authority
JP
Japan
Prior art keywords
beraprost
salt
administration
therapeutic agent
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51394793A
Other languages
English (en)
Japanese (ja)
Inventor
誠 奥村
敏明 奥田
中村　　勉
基之 矢島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Toray Industries Inc
Original Assignee
Kaken Pharmaceutical Co Ltd
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd, Toray Industries Inc filed Critical Kaken Pharmaceutical Co Ltd
Application granted granted Critical
Publication of JP3209427B2 publication Critical patent/JP3209427B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
JP51394793A 1992-02-07 1993-02-05 創傷または痔疾治療剤 Expired - Fee Related JP3209427B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2280892 1992-02-07
JP4-189867 1992-06-24
JP4-22808 1992-06-24
JP18986792 1992-06-24
PCT/JP1993/000151 WO1993015739A1 (en) 1992-02-07 1993-02-05 Remedy for wound or hemorrhoid

Publications (1)

Publication Number Publication Date
JP3209427B2 true JP3209427B2 (ja) 2001-09-17

Family

ID=26360087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51394793A Expired - Fee Related JP3209427B2 (ja) 1992-02-07 1993-02-05 創傷または痔疾治療剤

Country Status (8)

Country Link
US (3) US5403867A (OSRAM)
EP (1) EP0583482B1 (OSRAM)
JP (1) JP3209427B2 (OSRAM)
AT (1) ATE188119T1 (OSRAM)
CA (1) CA2107669C (OSRAM)
DE (1) DE69327432T2 (OSRAM)
TW (1) TW234691B (OSRAM)
WO (1) WO1993015739A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
JP3209427B2 (ja) * 1992-02-07 2001-09-17 科研製薬株式会社 創傷または痔疾治療剤
JP3971454B2 (ja) * 1993-10-29 2007-09-05 ザ トラスティーズ オブ ボストン ユニバーシティ 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
IT1269634B (it) * 1994-05-06 1997-04-08 Indena Spa Medicamento topico ad attivita' cicatrizzante
WO1995033465A1 (fr) * 1994-06-02 1995-12-14 Teijin Limited Composition pharmaceutique pour le traitement de troubles du systeme circulatoire peripherique
CA2181364A1 (en) * 1994-11-17 1996-05-30 Kaneto Uekama Preparation for percutaneous absorption
AU4732096A (en) * 1995-02-27 1996-09-18 Toray Industries, Inc. Remedy for pulmonary heart
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5869059A (en) * 1996-01-16 1999-02-09 Mon's Tea Partnership Herbal composition for hemorrhoid treatment
CA2324426A1 (en) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
US6365198B1 (en) * 2001-01-28 2002-04-02 Gulf Pharmaceutical Industries Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids
US20040266880A1 (en) * 2002-02-22 2004-12-30 Fumie Sato Antipruritics
KR100904583B1 (ko) * 2002-08-09 2009-06-25 다이쇼 세이야꾸 가부시끼가이샤 지양제
US7737182B2 (en) * 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
JP2006522136A (ja) 2003-04-02 2006-09-28 ネックスメド ホールディングス インコーポレイテッド プロスタグランジン組成物および血管痙攣の治療のためのその使用
WO2005000316A1 (ja) * 2003-06-25 2005-01-06 Cardiovascular Institute, Ltd. 性交機能改善用外用製剤
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
MA33899B1 (fr) 2009-12-08 2013-01-02 Hemaquest Pharmaceuticals Inc Procedes et regimes a faible dose pour des troubles des globules rouges
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
CA2838109C (en) 2011-04-07 2020-06-09 Nexmed Holdings, Inc. Topical semisolid prostaglandin e1 composition for treating raynaud's disease
US9345678B2 (en) 2013-03-13 2016-05-24 Allergan, Inc. Prostanoid receptor agonist compounds and methods of use for same
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK142235B (da) * 1974-12-20 1980-09-29 Yamanouchi Pharma Co Ltd Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater.
US4025645A (en) * 1976-01-27 1977-05-24 Jelenko Iii Carl Non-steroid topical agent for alleviating inflammation in mammals
GB1595056A (en) * 1976-10-12 1981-08-05 Wellcome Found Pharmaceutical combination
JPS5391110A (en) * 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
DE3162659D1 (en) * 1980-07-22 1984-04-19 Ono Pharmaceutical Co 9,11-methano-13-aza-11a-carbathrombanoic acid analogues and pharmaceutical use thereof
DE3631169A1 (de) * 1986-09-11 1988-03-24 Schering Ag Prostacyclinderivate enthaltende mittel fuer die topische anwendung
DE3886936T2 (de) * 1987-10-16 1994-04-28 Toray Industries 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLEN 2-PGI-DERIVATE, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG.
JPH0311017A (ja) * 1989-06-06 1991-01-18 Green Cross Corp:The プロスタグランジンｅ↓１含有薬剤組成物
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
JP3209427B2 (ja) * 1992-02-07 2001-09-17 科研製薬株式会社 創傷または痔疾治療剤
SG66248A1 (en) * 1993-02-03 1999-07-20 Teijin Ltd External skin treatment agent composition containing prostacyclins as active ingredient

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｉｓｒ．Ｊ．Ｍｅｄ．Ｓｃｉ．，（１９８７），２３（７），ｐ８４１−８４３
ＰＲＯＳＴＡＧＬＡＮＤＩＮＳ，（１９７５），１０（４），ｐ５７３−５７９
愛院大歯誌、（１９８８）、第２６巻第１号、ｐ１１５−１５７

Also Published As

Publication number Publication date
EP0583482A1 (en) 1994-02-23
ATE188119T1 (de) 2000-01-15
EP0583482A4 (en) 1995-05-03
US5852050A (en) 1998-12-22
DE69327432T2 (de) 2000-05-18
DE69327432D1 (de) 2000-02-03
US5679707A (en) 1997-10-21
WO1993015739A1 (en) 1993-08-19
CA2107669C (en) 2004-06-01
US5403867A (en) 1995-04-04
TW234691B (OSRAM) 1994-11-21
CA2107669A1 (en) 1993-08-08
EP0583482B1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
JP3209427B2 (ja) 創傷または痔疾治療剤
TWI874298B (zh) 包含孟魯司特的局部調配物及與貽貝黏著蛋白的組合
RU2502519C2 (ru) Терапевтическое средство для лечения ринита
ES2216279T3 (es) Uso de misoprostol y/o acido de misoprostol para el tratamiento de la disfuncion erectil.
WO1991004034A1 (en) Topical preparation for treatment of aphthous ulcers and other lesions
PT91597B (pt) Processo para tratar lesoes cutaneas usando antagonistas do receptor de tromboxano a2 como o 7-oxabiciclo-{2.2.1}hept-2-1}5-heptenoico
JP7530354B2 (ja) 肛門直腸疾患の治療のための局所的なアムロジピン塩
EA006015B1 (ru) Содержащая циклезонид фармацевтическая композиция, предназначенная для нанесения на слизистую оболочку
JPH07196516A (ja) 痔疾患治療剤
WO2020143744A1 (en) New formulations containing leukotriene receptor antagonists
AU2022256582B2 (en) Methods for treating diabetic ulcer
ITMI982569A1 (it) "composizione farmaceutica comprendente un composto organico donatoredi ossido nitrico"
KR0174763B1 (ko) 창상 또는 치질 치료제
CN1167446C (zh) 一种治疗宫颈炎及宫颈糜烂的中药凝胶剂及制备方法
JPWO2016121147A1 (ja) 注腸剤
CN102448463A (zh) 用于调节紧密连接蛋白介导的功能和治疗皮肤病的包含前列腺素衍生物的药物组合物
WO2023182468A1 (ja) 創傷治療用組成物
JPS649964B2 (OSRAM)
HK40082364A (en) Topical formulations comprising combinations of montelukast and mussel adhesion proteins
JPH04275215A (ja) 消炎鎮痛外用剤
JP2000186042A (ja) ラクトン誘導体を用いる炎症性呼吸器疾患治療剤
JP2003521467A5 (OSRAM)
JP2004262776A (ja) 血管新生促進剤

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090713

Year of fee payment: 8

LAPS Cancellation because of no payment of annual fees